BioCryst Pharma (BCRX) Reports In-Line Q3 Loss of 14c/Share

November 5, 2013 6:16 AM

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found